Agilent Technologies Gestione
Criteri Gestione verificati 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Padraig McDonnell
Amministratore delegato
US$12.8m
Compenso totale
| Percentuale dello stipendio del CEO | 8.90% |
| Mandato del CEO | 2yrs |
| Proprietà del CEO | 0.02% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 7.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento dell'analisi • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.Aggiornamento dell'analisi • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Aggiornamento dell'analisi • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).Aggiornamento dell'analisi • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Seeking Alpha • Mar 10
Why Agilent Technologies Just Paid $950 Million For Biocare Medical
Summary Agilent Technologies (A) acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. A trades below historical valuation multiples, presenting an opportunity if management executes on diagnostics expansion and leverages its global distribution to scale Biocare’s offerings. 1Q26 results showed 7% reported revenue growth to $1.80B, with non-GAAP EPS up 4% year-over-year, and management raised FY26 guidance for both revenue and EPS. The Biocare deal accelerates Agilent’s shift toward higher-margin, recurring revenue, with management expecting positive EPS contribution within 12 months post-close. Read the full article on Seeking AlphaAggiornamento dell'analisi • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.Aggiornamento dell'analisi • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).Aggiornamento dell'analisi • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).Aggiornamento dell'analisi • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).Articolo di analisi • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...Aggiornamento dell'analisi • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).Aggiornamento dell'analisi • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.Articolo di analisi • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...Aggiornamento dell'analisi • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.Aggiornamento dell'analisi • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.Aggiornamento dell'analisi • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).Aggiornamento dell'analisi • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.Aggiornamento dell'analisi • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.Articolo di analisi • Aug 03
Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agilent Technologies fair value estimate is US$114 With US$114...Articolo di analisi • Jul 01
What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
Today we're going to take a look at the well-established Agilent Technologies, Inc. ( NYSE:A ). The company's stock saw...Seeking Alpha • Apr 24
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Summary City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. Despite macroeconomic risks, Series A's deep discount and commendable yield, along with manageable leverage ratios, led to us deeming it a 'Buy.' Read the full article on Seeking AlphaSeeking Alpha • Apr 07
Tariffs And Tactics: Agilent's Path Through Trade Disruption
Summary The April 2025 "Liberation Day" tariffs impose a 10% baseline tariff on all imports and additional surcharges, significantly impacting Agilent Technologies' cost structure and supply chain. Agilent's diversified global manufacturing footprint and strategic localization in China help mitigate some tariff impacts, but higher costs and competitive pressures remain concerns. Despite initial projections of modest financial impact, prolonged tariffs could necessitate further operational shifts, including relocating production and localizing R&D to maintain market access. Agilent's strong brand, advanced technology, and flexible supply chain position it to navigate tariff challenges, with potential long-term benefits from a more resilient global network. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Agilent Technologies: Recent Price Weakness Makes This Stock A Buy
Summary Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jan 31 2026 | n/a | n/a | US$1b |
| Oct 31 2025 | US$13m | US$1m | US$1b |
| Jul 31 2025 | n/a | n/a | US$1b |
| Apr 30 2025 | n/a | n/a | US$1b |
| Jan 31 2025 | n/a | n/a | US$1b |
| Oct 31 2024 | US$9m | US$870k | US$1b |
| Jul 31 2024 | n/a | n/a | US$1b |
| Apr 30 2024 | n/a | n/a | US$1b |
| Jan 31 2024 | n/a | n/a | US$1b |
| Oct 31 2023 | US$3m | US$606k | US$1b |
| Jul 31 2023 | n/a | n/a | US$1b |
| Apr 30 2023 | n/a | n/a | US$1b |
| Jan 31 2023 | n/a | n/a | US$1b |
| Oct 31 2022 | US$3m | US$571k | US$1b |
| Jul 31 2022 | n/a | n/a | US$1b |
| Apr 30 2022 | n/a | n/a | US$1b |
| Jan 31 2022 | n/a | n/a | US$1b |
| Oct 31 2021 | US$3m | US$495k | US$1b |
Compensazione vs Mercato: La retribuzione totale di Padraig ($USD 12.83M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 14.80M ).
Compensazione vs guadagni: La retribuzione di Padraig è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Padraig McDonnell (53 yo)
2yrs
Mandato
US$12,827,236
Compensazione
Mr. Padraig McDonnell serves as its CEO, President & Director since May 01, 2024. He served as Senior Vice President at Agilent Technologies, Inc. since May 1, 2020 until February 2024 and served as Chief...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$12.83m | 0.023% $ 7.4m | |
| VP, Corporate Controller & Principal Accounting Officer | no data | US$2.70m | 0.0017% $ 529.2k | |
| Senior VP & President of Agilent CrossLab Group | 2.3yrs | US$3.21m | 0.010% $ 3.2m | |
| Senior VP and President of Life Sciences & Diagnostics Markets Group | 2yrs | US$3.87m | 0.00059% $ 185.8k | |
| Senior VP & Secretary | 1.8yrs | US$3.66m | 0.00043% $ 135.4k | |
| Senior VP | less than a year | Nessun dato | Nessun dato | |
| Senior VP & Chief Technology Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Legal Officer | no data | Nessun dato | 0.000010% $ 3.1k | |
| Senior VP | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | 1.2yrs | Nessun dato | 0.00054% $ 170.1k | |
| MD of UK & Ireland Operations and VP of Human Resources - Europe | 21.3yrs | Nessun dato | Nessun dato |
1.8yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di A non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 2yrs | US$12.83m | 0.023% $ 7.4m | |
| Independent Director | 4.5yrs | US$325.43k | Nessun dato | |
| Independent Director | 15.3yrs | US$345.43k | 0.0063% $ 2.0m | |
| Independent Director | 8.2yrs | US$350.43k | Nessun dato | |
| Independent Non-Executive Chairman | 23yrs | US$480.43k | 0.022% $ 7.0m | |
| Independent Director | 1yr | US$264.63k | 0.00095% $ 299.2k | |
| Independent Director | 10.8yrs | US$335.43k | Nessun dato | |
| Independent Director | 1yr | US$269.15k | 0.0014% $ 428.4k | |
| Independent Director | 7.2yrs | US$325.43k | 0.0059% $ 1.9m | |
| Independent Director | 4.7yrs | US$335.43k | 0.0025% $ 796.9k | |
| Independent Director | 10.7yrs | US$335.43k | 0.0084% $ 2.6m |
7.2yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di A sono considerati esperti (durata media dell'incarico 7.2 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/12 00:54 |
| Prezzo dell'azione a fine giornata | 2026/05/12 00:00 |
| Utili | 2026/01/31 |
| Utili annuali | 2025/10/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Agilent Technologies, Inc. è coperta da 34 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |